Moderna's new coronavirus vaccine, which showed 94.1% efficacy in clinical trials, filed an emergency license with the authorities
Moderna, a biotechnology company that develops the new coronavirus vaccine 'mRNA-1273,' has announced the final results of a clinical trial involving approximately 30,000 subjects. According to it, the effectiveness of the vaccine was 94.1%, and the effectiveness against aggravation was 100%. In response, Moderna has applied for an emergency license from the US Food and Drug Administration (FDA).
Moderna Announces Primary Efficacy Analysis in Phase 3 COVE Study for Its COVID-19 Vaccine Candidate and Filing Today with US FDA for Emergency Use Authorization | Moderna, Inc.
'Absolutely remarkable': No one who got Moderna's vaccine in trial developed severe COVID-19 | Science | AAAS
Unlike conventional vaccines that detoxify or attenuate the virus itself and purify it, mRNA-1273 is an ' mRNA vaccine ' that uses mRNA to acquire immunity, which simplifies the development and manufacturing process faster than before. , Features higher manufacturing cost performance.
In fact, mRNA-1273 was the world's first human clinical trial of the new coronavirus vaccine on March 16, 2020, just two months after the acquisition of the new coronavirus genome sequence.
The world's first human clinical trial of the new coronavirus vaccine has started --GIGAZINE
Moderna's mRNA-1273 was developed as part of the Operation Warp Speed Program, which promotes the development project for the new coronavirus vaccine, and will be in Phase III (Phase 3), the final stage of clinical trials, in mid-November 2020. ) Was made, and it was announced that the effectiveness of 94.5% was confirmed.
Moderna announces that the new corona vaccine under development has achieved '94.5% preventive effect' in clinical trials --GIGAZINE
According to the final report, mRNA-1273 functioned to the same extent in all different groups, ethnicities and genders. 'MRNA-1273 is highly effective against mild and severe symptoms and is most effective when the vaccine is given to people at highest risk of coronavirus infection,' said Stephane Bancel, CEO of Moderna. In other words, priority should be given to healthcare workers, the elderly, diabetic patients, obesity, and people with heart disease. '
Moderna hopes to provide the US government with 20 million doses of vaccine by the end of the year, and said it plans to provide 50 million doses, taking into account other countries that have pre-purchased contracts with the United States.
According to CEO Vansel, the cost of vaccination in developed countries ranges from $ 32 (about 3300 yen) to $ 37 (about 3800 yen) each time. However, Moderna is affiliated with the COVID-19 Vaccines Global Access Facility, a non-profit organization that promotes vaccine equality, and it is possible that prices will be lower in low-income countries.
in Science, Posted by log1i_yk